Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01758-6/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_infocusoncology_esmo24&_hsenc=p2ANqtz-8juXbgoXV8Q2JgwdFDIrswzPIT2y_bmhtB1C3cV80kzxXm-MY_NfpiXoD8s3xCc55ditw3mp1j7-cgvh6ayZfeqbtQVA&_hsmi=325179166&utm_content=325179166&utm_source=hs_email